Honz Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
August 27, 2021 at 01:40 pm
Share
Honz Pharmaceutical Co., Ltd. announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was CNY 423.547 million compared to CNY 411.318 million a year ago. Operating loss was CNY 49.113 million compared to operating Income of CNY 13.829 million a year ago. Net loss was CNY 57.637 million compared to net income of CNY 7.450 million a year ago. Basic loss per share from continuing operations was CNY 0.1281 compared to basic earnings per share from continuing operations of CNY 0.0166 a year ago.
HONZ PHARMACEUTICAL CO., LTD., formerly HAINAN HONZ PHARMACEUTICAL CO., LTD., is principally engaged in the research, development, production and distribution of drugs for children. The Company provides western medicines and Chinese patent drugs, including antipyretic and analgesic drugs, cold drugs, antibiotics drugs, respiratory system drugs, digestant and arresting convulsion drugs, as well as nutrition drugs, among others. The Company's products include nimesulide granules, cefminox sodium for injection, Zhike Juhong granules, Ganmao Qingre granules, artificial cow-bezoar and chlorphenamine maleate granules, cefaclor granules, carbocisteine granules, Jianerle granules, pediatric four vitaminsand calcium gluconate granules, as well as ribavirin pellets and Norfloxacin capsules for adults.